ArticleJournal of cellular and molecular medicine2026
Inhibition of Calcium-Sensing Receptor Suppresses Malignant Behaviours of Human Hepatocellular Carcinoma.
Article in Journal of cellular and molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Hepatocellular carcinoma (HCC) continues to pose significant worldwide health burdens due to restricted treatment alternatives and unfavourable prognosis. This investigation reveals the pivotal involvement of calcium-sensing receptor (CaSR) in HCC advancement and its potential as a promising therapeutic target. Through pharmacological blockade with NPS-2143 and genetic knockdown using siRNA, we found that CaSR inhibition substantially reduced HCC cell proliferation, migration, and invasion, while promoting apoptotic cell death in HepG2 and SMMC-7721 cells. At the molecular level, CaSR interference triggered p38 MAPK activation, while inhibiting the ERK1/2 cascade, resulting in diminished expression of proliferation indicators (PCNA), metastatic markers (MMP-2/9), and cell survival proteins (Bcl-2), concurrent with elevated levels of apoptosis mediators (Bax, cleaved caspase-3). In vivo, NPS-2143 significantly suppressed xenograft tumour growth. Western blotting of xenograft tumour tissues further showed increased p-p38/p38 and Bax levels and decreased p-ERK/ERK, MMP-9, and Bcl-2 levels, consistent with the in vitro findings. Additional validation in a male nude mouse xenograft model using Huh7 cells further supported the anti-tumour effect of NPS-2143 in another independent HCC model. These findings suggest that CaSR facilitates malignant HCC cebehaviours through MAPK signalling and may represent a potential therapeutic target for HCC treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.